The market cap is too small for most instos to even look at it let alone invest. They have mandates that stop them from buying this sort of thing. Most brokers no longer cover this stock and have moved on.
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress